BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
This is one of my gem picks and future investments once I can infuse some cash into my portfolio (a little difficult when moving). The company is nearing completion of a major overhaul - following suit of many other paper companies - and has been whacked in the process. However, with a fair book value of $38.42 per share (and growing) there is no reason to believe patient shareholders won't reap significant gains. That represents a 190% gain to $12 per share.
RFP is the perfect stock to break the back of those who religiously hold onto the metric of P/E. At fair book value this company would have a current P/E of nearly 100 (!!!) but it wouldn't be overvalued compared to a liquidation or acquisition scenario. If the company wasn't restructuring an earned a modest $1.74 per share (TTM) it would have a P/E of just 20 at $38.42 per share. It would be wise to look into this company more closely before the big players catch on.
As a bioprocess engineer (my curriculum was closely related to paper engineering) I believe this is a very sweet opportunity for investors. Once I purchase shares I will certainly add a comment and disclose my entry point.